Haloperidol and the butyrophenones.
D000342:Affective Symptoms / Q000188:drug therapy; D000613:Aminobutyrates / Q000378:metabolism; D001714:Bipolar Disorder / Q000188:drug therapy; D001921:Brain / Q000187:drug effects; D001927:Brain Diseases / Q000188:drug therapy; D002090:Butyrophenones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002463:Cell Membrane Permeability / Q000187:drug effects; D003214:Conditioning, Classical; D004298:Dopamine / Q000378:metabolism; D004569:Electroencephalography; D006220:Haloperidol / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D009497:Neurotic Disorders / Q000188:drug therapy; D009638:Norepinephrine / Q000378:metabolism; D011581:Psychological Tests; D011955:Receptors, Drug / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D013268:Stimulation, Chemical
D000613:Aminobutyrates; D002090:Butyrophenones; D011955:Receptors, Drug; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine